Ubiquitin Activating Enzyme E1

<strong>Ubiquitin Activating Enzyme E1</strong>_x000D_ <strong>Catalog number:</strong> B2013366_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 118 g/mol_x000D_ <strong>Supplied as:</strong> Liquid_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20¬∞C_x000D_ <strong>Keywords:</strong> AMCX1, POC20, UBA1, UBE1, Ubiquitin E1_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Grayson PC, Patel BA, Young NS. VEXAS syndrome Blood. 2021 Jul 1;137(26):3591-3594._x000D_ 2: Hyer ML, Milhollen MA, Ciavarri J, Fleming P, Traore T, Sappal D, Huck J, Shi J, Gavin J, Brownell J, Yang Y, Stringer B, Griffin R, Bruzzese F, Soucy T, Duffy J, Rabino C, Riceberg J, Hoar K, Lublinsky A, Menon S, Sintchak M, Bump N, Pulukuri SM, Langston S, Tirrell S, Kuranda M, Veiby P, Newcomb J, Li P, Wu JT, Powe J, Dick LR, Greenspan P, Galvin K, Manfredi M, Claiborne C, Amidon BS, Bence NF. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment Nat Med. 2018 Feb;24(2):186-193._x000D_ 3: Lambert-Smith IA, Saunders DN, Yerbury JJ. The pivotal role of ubiquitin-activating enzyme E1 (UBA1) in neuronal health and neurodegeneration Int J Biochem Cell Biol. 2020 Jun;123:105746._x000D_ 4: Groarke EM, Dulau-Florea AE, Kanthi Y. Thrombotic manifestations of VEXAS syndrome Semin Hematol. 2021 Oct;58(4):230-238._x000D_ 5: Koster MJ, Warrington KJ. VEXAS within the spectrum of rheumatologic disease Semin Hematol. 2021 Oct;58(4):218-225._x000D_ 6: Panchamia B, Raimalani V, Prashar V, Kumar M, Ratna Prabha C. Structural and Functional Characterisation of the Domains of Ubiquitin-Activating Enzyme (E1) of Saccharomyces cerevisiae Cell Biochem Biophys. 2020 Sep;78(3):309-319._x000D_ 7: Afsahi V, Christensen RE, Alam M. VEXAS syndrome in dermatology Arch Dermatol Res. 2023 Mar;315(2):161-164._x000D_ 8: Barghout SH, Schimmer AD. E1 Enzymes as Therapeutic Targets in Cancer Pharmacol Rev. 2021 Jan;73(1):1-58._x000D_ 9: Shaukat F, Hart M, Burns T, Bansal P. UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review Mod Rheumatol Case Rep. 2022 Jan 7;6(1):134-139._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/7673335">10: Nagai Y, Kaneda S, Nomura K, Yasuda H, Seno T, Yamao F. Ubiquitin-activating enzyme, E1, is phosphorylated in mammalian cells by the protein kinase Cdc2 J Cell Sci. 1995 Jun;108 ( Pt 6):2145-52. </a>_x000D_ _x000D_ <strong>Products Related to Ubiquitin Activating Enzyme E1 can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>